New combo therapy aims to control advanced lung cancer
NCT ID NCT07414953
First seen Feb 19, 2026 · Last updated May 17, 2026 · Updated 15 times
Summary
This early-phase study tests a new drug called HS-10504 combined with other treatments for people with advanced non-small cell lung cancer that has worsened after prior therapy. The goal is to find safe doses and see if the combination can shrink tumors or slow the disease. About 400 adults with specific genetic mutations (EGFR or MET) will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.